A randomized controlled trial from Beni-Suef University Hospital in Egypt has found that combining a moderate dose of the statin rosuvastatin with the cholesterol-absorption blocker ezetimibe lowered LDL cholesterol to a greater degree than doubling the statin dose alone, while producing smaller relative increases in liver enzymes over 24 weeks. The study, published in Future Journal of Pharmaceutical Sciences, enrolled patients with dyslipidemia at moderate-to-high cardiovascular risk and compared two widely used lipid-lowering strategies head to head.
The trial screened 86 patients between July 2024 and July 2025, of whom 69 were randomized. After withdrawals and loss to follow-up, 60 participants completed the full 24-week follow-up, with 30 in each arm. One group received a fixed combination of rosuvastatin 10 mg plus ezetimibe 10 mg once daily; the other received high-intensity rosuvastatin 20 mg monotherapy. Because the regimens differed in the number of tablets, participants and treating physicians could not be blinded, but laboratory staff and the statistician remained unaware of treatment allocation. The trial was prospectively registered at ClinicalTrials.gov and reported according to CONSORT guidelines.
The primary efficacy endpoint was the absolute change in LDL cholesterol from baseline to week 24. Both regimens produced statistically significant LDL reductions compared with baseline, with p values below 0.001 in each group. At the end of follow-up, however, the combination group had significantly lower LDL cholesterol than the monotherapy group: 71.83 plus or minus 12.14 mg/dL versus 86.30 plus or minus 23.87 mg/dL, a difference that reached statistical significance at p = 0.004.
A subtler statistical picture emerged from the repeated-measures analysis. The treatment-by-time interaction for LDL cholesterol was not significant (F(1,58) = 0.033, p = 0.857), meaning the trajectory of LDL reduction over the 24 weeks was statistically comparable between the two strategies. In other words, both approaches lowered cholesterol at similar rates, but the combination arm ended at a lower final concentration. The authors attribute this to the complementary mechanisms of the two drugs: rosuvastatin inhibits hepatic cholesterol synthesis through blockade of HMG-CoA reductase, while ezetimibe inhibits intestinal cholesterol absorption via the Niemann-Pick C1-like 1 (NPC1L1) transporter on enterocytes.
Secondary lipid outcomes were largely comparable between the groups. Total cholesterol fell significantly in both arms, but post-treatment values did not differ significantly between them (148.76 versus 153.16 mg/dL, p = 0.522), and the treatment-by-time interaction was nonsignificant. Triglycerides also declined significantly in both groups, with a numerical but nonsignificant advantage for the combination arm (96.86 versus 109.76 mg/dL, p = 0.099). HDL cholesterol rose significantly only in the monotherapy group, from 41.03 to 45.63 mg/dL, yet between-group differences were not significant at any time point, and the authors caution that the clinical impact of this isolated within-group change is likely limited.
The safety findings require careful reading, and the study itself emphasizes this. Both regimens were associated with statistically significant increases from baseline in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatine kinase (CK), all with p values below 0.001. Absolute post-treatment values, however, did not differ significantly between groups for any of these markers (AST p > 0.999; ALT p = 0.489; CK p = 0.922), and no significant treatment-by-time interactions were observed. Crucially, mean liver enzyme values in both groups remained well below the accepted threshold of three times the upper limit of normal throughout follow-up, indicating no clinically relevant hepatotoxicity in either arm.
Where the groups did diverge was in relative change from baseline. Median percentage increases in AST were significantly smaller with combination therapy (15.38% versus 35.71%, p = 0.015), as were ALT increases (14.28% versus 21.11%, p = 0.018). Percentage changes in LDL cholesterol, total cholesterol, triglycerides, HDL cholesterol, and CK did not differ significantly between groups. The authors stress that this statistical significance in liver enzymes reflects differences in the magnitude of change from baseline rather than clinically meaningful liver injury, since absolute enzyme concentrations remained comparable and within acceptable ranges.
No major adverse cardiovascular events occurred during the 24-week study period, and no clinically significant muscle toxicity was reported. The investigators nevertheless acknowledge an important gap: the trial did not systematically evaluate statin-associated muscle symptoms such as myalgia or weakness, and adverse events were not graded with a standardized severity system such as CTCAE. Conclusions about overall muscle safety therefore remain tentative, even though biochemical CK monitoring showed only modest, comparable increases in both arms.
The study’s design and limitations frame how far these results can be extended. It was a single-center, open-label, parallel-group trial analyzed on a per-protocol basis, which may introduce attrition bias compared with an intention-to-treat approach. The sample was powered primarily to detect differences in LDL cholesterol reduction, not infrequent safety events or cardiovascular outcomes, and the study was explicitly not designed to establish superiority or non-inferiority for clinical cardiovascular endpoints. The 24-week follow-up also prevents any assessment of long-term durability, delayed adverse effects, or event reduction. The authors note that these findings should be interpreted as evidence on short-term biochemical efficacy and tolerability rather than long-term cardiovascular benefit.
Even with those caveats, the trial adds to a substantial evidence base. Previous randomized trials and meta-analyses have shown greater LDL reductions when ezetimibe is added to statin therapy, particularly in high-risk patients, and the IMPROVE-IT trial demonstrated that adding ezetimibe to a statin improved cardiovascular outcomes after acute coronary syndrome. What has been scarcer is direct randomized evidence comparing moderate-intensity statin-ezetimibe combination therapy against high-intensity statin monotherapy with attention to short-term safety. The new results suggest that for selected patients requiring intensive LDL reduction, combining moderate-dose rosuvastatin with ezetimibe achieves comparable or better lipid lowering with lower relative liver enzyme changes, potentially allowing reduced statin exposure. The authors call for larger, multicenter randomized trials with longer follow-up, standardized adverse-event grading, and intention-to-treat analyses to determine whether these biochemical advantages translate into sustained clinical benefit.
Subject of Research: A randomized controlled trial comparing rosuvastatin-ezetimibe combination therapy with high-intensity rosuvastatin monotherapy for lipid lowering and short-term safety in dyslipidemia.
Article Title: Evaluation of relative safety and therapeutic efficacy of antihyperlipidemic drug regimens used alone or in combination in cardiovascular disease: randomized controlled study
Article References: Elsaeed, N. K., Abdelmoety, R. H., Elyamani, E., Mahmoud, L. M., Zidan, M., Matter, L. M., Imam, M. S., Alosaimi, F. M., Alosaimi, F. S., Almehery, A. A., Asiri, A. A., Maadi, R. A., Rabea, H., & Abdelrahman, M. A. (2026). Evaluation of relative safety and therapeutic efficacy of antihyperlipidemic drug regimens used alone or in combination in cardiovascular disease: randomized controlled study. Future Journal of Pharmaceutical Sciences, 12(1), Article 82. https://doi.org/10.1186/s43094-026-01013-7
Image Credits: AI Generated
DOI: 10.1186/s43094-026-01013-7
Keywords: rosuvastatin, ezetimibe, LDL cholesterol, dyslipidemia, randomized controlled trial, liver enzymes, statin combination therapy, cardiovascular risk, NPC1L1, creatinine kinase, lipid-lowering, hepatotoxicity
News Source: Ophelia Keating. (October 29, 2026). Rosuvastatin Plus Ezetimibe Lowers LDL Cholesterol More Than High-Dose Statin Alone. Scienmag.
